Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non−Small Cell Lung Cancer

IMPORTANCE: Immune checkpoint inhibitor (ICI) monotherapy with pembrolizumab and ICI plus chemotherapy have been approved as first-line treatments for non–small cell lung cancer (NSCLC) for patients with a programmed cell death ligand–1 (PD-L1) tumor proportion score (TPS) of 50% or more, but the ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawachi, Hayato, Yamada, Tadaaki, Tamiya, Motohiro, Negi, Yoshiki, Goto, Yasuhiro, Nakao, Akira, Shiotsu, Shinsuke, Tanimura, Keiko, Takeda, Takayuki, Okada, Asuka, Harada, Taishi, Date, Koji, Chihara, Yusuke, Hasegawa, Isao, Tamiya, Nobuyo, Ishida, Masaki, Katayama, Yuki, Morimoto, Kenji, Iwasaku, Masahiro, Tokuda, Shinsaku, Kijima, Takashi, Takayama, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10336622/
https://www.ncbi.nlm.nih.gov/pubmed/37432682
http://dx.doi.org/10.1001/jamanetworkopen.2023.22915

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10336622/
https://www.ncbi.nlm.nih.gov/pubmed/37432682
http://dx.doi.org/10.1001/jamanetworkopen.2023.22915

Ejemplares similares